İngiltere’de Southampton Üniversitesi’nde geliştirilen bir ilacın sonuçları olumlu geldi.
Covid-19 tedavisinde kullanılan ilacın yoğun bakım ihtiyacını yüzde 79 oranında azalttığı belirtildi.
Tedavi döneminde (ilk günden 16. güne kadar) ciddi hastalık (ventilasyon gerektiren veya ölümle sonuçlanan) gelişme riski, SNG001 alan hastalar için plasebo alan hastalara kıyasla% 79 oranında önemli ölçüde azalmıştır.
Üniversiteyle birlikte ilacı geliştiren Synairgen şirketinin kısa zamanda resmi verileri açıklaması bekleniyor.
“The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lung’s immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus,” Professor Tom Wilkinson, Professor of Respiratory Medicine at the University of Southampton and trial chief investigator.
“Recognising that SARS-CoV-2 is known to have evolved to evade the initial antiviral response of the lung, our inhaled treatment of giving high local concentrations of interferon beta, a naturally occurring antiviral protein, restores the lung’s ability to neutralise the virus, or any mutation of the virus or co-infection with another respiratory virus such as influenza or RSV, as could be encountered in the winter if there is a resurgence of COVID-19,” added Professor Stephen Holgate CBE, Medical Research Council Clinical Professor of Immunopharmacology at the University of Southampton and Co-Founder of Synairgen.
